1027223-19-3

Upstream product

• 1026432-98-3 [1-(4-fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-methyl-carbamic acid tert-butyl ester 
• 193085-53-9 (2R)-2-(N-tert-butoxycarbonyl-N-methylamino)-3-(4-fluorophenyl)propionic acid 
• 5382-16-1 4-HYDROXYPIPERIDINE 

Downstream Products

• 1026292-85-2 N-[1-(4-fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-N-methyl-2-methylamino-3-naphthalen-2-yl-propionamide 
• 1026849-16-0 {(E)-4-[((R)-1-{[(R)-1-(4-Fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 1025877-05-7 {(E)-4-[((R)-1-{[(R)-1-(4-Fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1,3-trimethyl-but-3-enyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency

In order to obtain more potent growth hormone secretagogues, a comparison of ipamorelin and NN703 suggested the addition of a polar group at the C-terminus of NN703. A study was conducted using constrained amines for this purpose. Here, substituted 4-piperidinylamino- and 4-dimethylaminopiperidino-substitutents were found to give the most active compounds. A replacement of the 4-dimethylaminopiperidino-substituent with 4-hydroxypiperidino resulted in a series of compounds, which showed in vitro activity with EC50 values in the low nanomolar range, and favourable kinetic properties, such as 40% oral bioavailability. The most promising compound was also tested in a swine in vivo model, resulting in a growth hormone level with a Cmax of over 40 ng mL-1.